<DOC>
	<DOCNO>NCT00336583</DOCNO>
	<brief_summary>Oxaliplatin use instead cisplatin well-known salvage regimen etoposide , methylprednisolone , cytarabine cisplatin ( ESHAP ) . Clinical efficacy toxicity ESHAOX salvage regimen evaluate refractory relapse non-Hodgkin 's lymphoma patient .</brief_summary>
	<brief_title>Etoposide , Methylprednisolone , High-dose Cytarabine Oxaliplatin 2nd Line Therapy Non-Hodgkin 's Lymphoma ( NHL )</brief_title>
	<detailed_description>Patients aggressive non-Hodgkin 's lymphoma ( NHL ) know malignancy consider curable many case . However , diagnosis refractory relapse disease devastate treatment difficult regimen chemotherapy use salvage therapy available limited number . ESHAP , consist etoposide , methylprednisolone , high-dose cytarabine cisplatin , one commonly use salvage regimen , show efficacy feasibility . But often require discontinuation treatment due myelosuppression , neuropathy renal toxicity , also impede treatment . Oxaliplatin , platinum coordination complex oxalato-ligand leave group 1,2-diaminocyclohexane carrier , possess high cytotoxic potency molar basis cisplatin carboplatin , report active patient NHL single agent . In addition , substitution cisplatin oxaliplatin DHAP regimen , another commonly use one relapsed refractory NHL , show meaningful anti-tumor activity favorable toxicity profile . Based preclinical clinical finding , conduct multi-center phase II study ESHAOX , substitute oxaliplatin cisplatin ESHAP regimen , evaluate efficacy toxicity profile patient recurrent refractory NHL .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Previously histologically confirm aggressive lymphoma , define accord WHO classification ( except Burkitt 's lymphoma , lymphoblastic lymphoma ) Failure achieve complete remission initial induction chemotherapy , recurrent disease Performance status ( ECOG ) ≤3 Age ≤ 75 Treated least one CHOP CHOPderived doxorubicin contain regimen At least one unidimensionally measurable lesion ( ) define ; ≥2 cm conventional CT ≥ 1 cm spiral CT skin lesion ( photograph take ) measurable lesion physical examination Adequate organ function define ; ANC &gt; 1,500/ul , platelet &gt; 75,000/ul , transaminase &lt; 3 X upper normal value ; bilirubin &lt; 2 mg % Written informed consent approve Institutional Review Board Any malignancy within past 5 year except skin basal cell ca CIS cervix Serious comorbid diseases Pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>oxaliplatin</keyword>
	<keyword>ESHAOX</keyword>
	<keyword>refractory</keyword>
	<keyword>relapse</keyword>
	<keyword>non-hodgkin 's lymphoma</keyword>
</DOC>